- Home
- GCTK vs JAGX Comparison
GCTK vs JAGX Comparison
Compare GCTK & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCTK
- JAGX
- Stock Information
- Founded
- GCTK 2001
- JAGX 2013
- Country
- GCTK United States
- JAGX United States
- Employees
- GCTK N/A
- JAGX N/A
- Industry
- GCTK Medical/Dental Instruments
- JAGX Biotechnology: Pharmaceutical Preparations
- Sector
- GCTK Health Care
- JAGX Health Care
- Exchange
- GCTK Nasdaq
- JAGX Nasdaq
- Market Cap
- GCTK 3.3M
- JAGX 3.9M
- IPO Year
- GCTK N/A
- JAGX N/A
- Fundamental
- Price
- GCTK $7.73
- JAGX $2.12
- Analyst Decision
- GCTK
- JAGX Strong Buy
- Analyst Count
- GCTK 0
- JAGX 1
- Target Price
- GCTK N/A
- JAGX $60.00
- AVG Volume (30 Days)
- GCTK 249.9K
- JAGX 217.2K
- Earning Date
- GCTK 11-13-2025
- JAGX 11-12-2025
- Dividend Yield
- GCTK N/A
- JAGX N/A
- EPS Growth
- GCTK N/A
- JAGX N/A
- EPS
- GCTK N/A
- JAGX N/A
- Revenue
- GCTK N/A
- JAGX $11,810,000.00
- Revenue This Year
- GCTK N/A
- JAGX $22.41
- Revenue Next Year
- GCTK N/A
- JAGX $30.00
- P/E Ratio
- GCTK N/A
- JAGX N/A
- Revenue Growth
- GCTK N/A
- JAGX 15.96
- 52 Week Low
- GCTK $4.22
- JAGX $1.57
- 52 Week High
- GCTK $2,928.00
- JAGX $33.25
- Technical
- Relative Strength Index (RSI)
- GCTK 57.17
- JAGX 51.41
- Support Level
- GCTK $7.02
- JAGX $1.93
- Resistance Level
- GCTK $9.05
- JAGX $2.42
- Average True Range (ATR)
- GCTK 0.58
- JAGX 0.19
- MACD
- GCTK 0.11
- JAGX 0.00
- Stochastic Oscillator
- GCTK 62.99
- JAGX 39.63
About GCTK GlucoTrack Inc.
GlucoTrack Inc is a medical device company. It is focused on defining novel approaches that make diabetes management more accurate and convenient for daily living. The company has developed the GlucoTrack model that measures real-time blood glucose levels. The Company is developing an long-term implantable continuous blood glucose monitoring (CBGM) system, built on healthcare technologies. It is designed to meet the critical needs of insulin-dependent individuals or those at risk of hypoglycemia in the U.S.
About JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.